Developer docs
API playgroundTry for free, no card

Search company profiles

Gelteq

Full company profile

uuid0000rlz

Namestring
Gelteq
Legal namestring
Gelteq Limited
Websiteurl
gelteq.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Gelteq is an Australian clinical-stage biotechnology company that has developed and patented a proprietary gel-based oral drug and nutrient delivery platform. Founded around 2016–2017 and headquartered at Monash Innovation Labs in Clayton, Victoria, the company's technology was co-developed with Monash University's Institute of Pharmaceutical Sciences (MIPS), ranked #1 globally for Pharmacy & Pharmacology in the 2024 QS World University Rankings. The core innovation is a gelification process that forms chemically and physically stable matrices capable of simultaneously integrating water-soluble and lipid-soluble compounds, addressing bioavailability and taste-masking challenges that affect over 40% of approved drugs. Preclinical and pharmacokinetic data report a 300% first-hour bioavailability improvement for oil-soluble compounds versus FDA-approved reference products and 38–45% improvement for water-soluble drugs such as antihistamines.

The company monetizes through a B2B licensing and partnership model. Gelteq licenses its proprietary gel formulations for white-label production by pharmaceutical, nutraceutical, and animal health partners; provides fee-for-service contract development and clinical support; and, through select distribution agreements, sells finished gel products directly. Named partners include Phynova and Reducose in pharmaceuticals, Healthy Extracts Inc. for US-based manufacturing and global distribution, Shenzhen Mana Health Management for exclusive China distribution of nutritional products (minimum ~USD 1.3M over three years), IDT Australia for cGMP manufacturing, and Kemin Industries for animal health validation. The company's commercial footprint spans Australia, the United States, and China, with active product candidates in veterinary antiparasitic clinical trials (FDA pathway), preclinical diabetes gels, and an antihistamine gel demonstrating pharmacokinetic gains.

Gelteq Limited is publicly traded on Nasdaq (GLTQ) and the ASX (GTQ), with a market capitalization of approximately $5.2M as of June 2026. The company is unprofitable, has 1–10 employees, and is currently funded in part by a $3.5M convertible debt facility (May 2026) to support clinical programs and commercial scale-up. It has received a Nasdaq minimum bid price deficiency notice with a compliance deadline of September 14, 2026, and its shares have declined approximately 71% over the prior year.

Short descriptiontext

Gelteq is an Australian biotech that licenses a patented gel-based oral drug and nutrient delivery platform to pharmaceutical, nutraceutical, and animal health partners globally, addressing bioavailability, taste masking, and swallowing challenges through proprietary gelification technology developed with Monash University.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersClayton, Australia
HQ citystring
Clayton
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral drug delivery, gel-based delivery, nutraceutical formulations, animal health products, bioavailability enhancement
Industry5 codes
PRIMARYAFAJACAH
Gelling Agents & Systems (Gelatin, Agar, Gellan, Konjac)
Agriculture & Food Production/Food Ingredients & Additives/Emulsifiers & Stabilizers (Lecithin, Mono/Diglycerides, Stabilizer Systems)
SECONDARYAFAJABAD
Gelatin & Collagen Hydrolysates (Animal-Based Gelling Agents)
Agriculture & Food Production/Food Ingredients & Additives/Starches & Hydrocolloids (Modified Starch, Gums, Thickeners)
SECONDARYCRADAOAD
Hydrocolloids, Thickeners & Gelling Agents (Pectin, Xanthan, Carrageenan, Gelatin)
SECONDARYHLAMAEAM
Generic & Private-Label Veterinary Pharmaceuticals
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMALAO
Specialty & Condition-Specific Nutraceuticals (e.g., Liver, Eye, Endocrine)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Drug Delivery Technology
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing
TypeLicensing Royalties
Description

Gelteq licenses its proprietary gel technology to pharmaceutical, nutraceutical, and animal health companies. Partners can white-label existing formulations or develop custom gel products using Gelteq's platform. The company retains full ownership of its intellectual property while enabling partners to manufacture and distribute gel-based products.

gelteq.com
2Manufacturing & Distribution Partnership
TypeProfessional Services
Description

Through partnerships like the Healthy Extracts MoU, Gelteq enables large-scale manufacturing and global distribution of gel products. Healthy Extracts serves as primary manufacturer and distributor while Gelteq provides formulations and technical transfer.

stocktitan.net
3Product Sales (Direct)
TypeOne Time License
Description

Direct sales of gel-based nutritional products through distribution agreements. The three-year agreement with Shenzhen Mana Health Management Co. specifies minimum revenue of approximately USD 1.3 million for nutritional products in China.

globenewswire.com
4Contract Development
TypeProfessional Services
Description

Fee-for-service formulation development and clinical trial support for pharmaceutical and nutraceutical companies seeking to leverage Gelteq's gel platform for their compounds.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Gelteq develops, licenses, and white-labels a proprietary patented gel-based oral drug delivery platform that converts pharmaceutical, nutraceutical, and animal health compounds into a stable, ingestible gel matrix. The company provides formulation development, contract research, white-label gel formulations, and partnership-based commercialization across pharmaceutical, nutraceutical, veterinary, and sports nutrition verticals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 300% increase in bioavailability of oil-soluble compounds in the first hour compared to FDA-approved reference product
+4 more records
Product overview1 text field

Gelteq offers a proprietary gel-based oral drug delivery platform as its core technology, enabling the conversion of existing compounds into gel-based formats. The company operates across four main market segments: pharmaceuticals (partnered with Phynova and Reducose), nutraceuticals, pet/veterinary health, and sports performance. Key product candidates include an antiparasitic veterinary drug in clinical trials for FDA approval, diabetes gel products developed with Monash University MIPS, and an antihistamine product showing 38-45% bioavailability improvements. Gelteq provides both custom formulation services and white-label market-ready gel products, with recent expansion through manufacturing partnerships including IDT Australia and Healthy Extracts Inc.

Product and service3 records
1Gelteq Gel-Based Oral Drug Delivery Platform
CategoryDrug Delivery Technology Platform
2Pharmaceutical Gel Products
CategoryPharmaceutical Drug Delivery
3Nutraceutical Gel Products
CategoryNutraceutical Delivery
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-06-12
Description

Successful completion of veterinary palatability trials demonstrating strong canine acceptance across various flavour profiles including products with natural bitter compounds. Results confirmed Gelteq technology's ability to effectively mask bitter flavours while improving palatability, validating the platform for veterinary pharmaceutical applications and supporting partnership discussions with animal health organizations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Strategic manufacturing and commercial partnership for gel-based nutraceutical products. Healthy Extracts serves as primary manufacturer, commercial seller, and distribution partner using Gelteq's proprietary formulations and technical expertise. Enables large-scale US manufacturing and global distribution while Gelteq retains full IP ownership. Partnership includes plans to expand into China and positions gel-based formats as a growth frontier in functional nutrition.

3Shenzhen Mana Health Management Co. Ltd.
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-09
Description

Three-year sales agreement for distribution of nutritional products in China. Deal expected to generate minimum revenue of approximately USD 1.3 million and represents strategic expansion into China's growing wellness market.

globenewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-17
Description

MoU for establishment of dedicated local manufacturing facility for gel-based pharmaceutical, nutraceutical, and animal health products. Leverages IDT's more than 50 years of pharmaceutical development and cGMP manufacturing expertise including FDA, TGA, and APVMA regulatory capabilities to support Gelteq's product scale-up for global markets.

5Monash University - Institute of Pharmaceutical Sciences (MIPS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Full-time R&D partnership with Monash University, ranked #1 globally in pharmaceutical science (2024 QS World University Rankings). MIPS formed as partnership between Monash University, Monash Institute of Pharmaceutical Science, and Victorian state government to create world-class biotechnology and medical research precinct. Global clients include GSK, Phillips, Roche, and Pfizer. MIPS serves as Gelteq's exclusive research and formulation development partner, with collaboration including development of diabetes-based gel products.

gelteq.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Catalent is a global CDMO with proprietary softgel and oral drug delivery platforms serving pharma and consumer health. It is the most direct analog to Gelteq's gel-based oral delivery concept, with a comparable B2B licensing and formulation-development model.

TypeDirect peer
Description

Evonik's Health Care division supplies specialty excipients and drug delivery technologies (including lipid-based and polymer systems such as EUDRAGIT) to pharmaceutical customers. Direct comparability to Gelteq's delivery-platform and excipient-licensing business model.

TypeDirect peer
Description

Roquette supplies pharmaceutical excipients including cyclodextrins and starches that address bioavailability challenges for poorly soluble APIs. Comparable in serving pharma formulation teams with solubilization technology, overlapping with Gelteq's core value proposition.

TypeDirect peer
Description

Ashland's pharmaceutical division provides controlled-release polymers and specialty excipients for oral solid dosage forms. Comparable to Gelteq as a specialty excipient/delivery platform supplier enabling partner drug reformulation.

TypeDirect peer
Description

AptarGroup is a global leader in drug delivery devices and dispensing systems for pharma, consumer health, and food/beverage. Comparable to Gelteq across target end-markets and B2B partnership model, though focused on device rather than formulation delivery.

TypeDirect peer
Description

Gattefossé specializes in lipid-based excipients and oral drug delivery systems for bioavailability enhancement. Directly comparable to Gelteq's dual water/lipid soluble delivery capability and pharma formulation partner model.

TypeDirect peer
Description

Colorcon provides controlled-release coatings, excipients, and formulation services to pharma and nutraceutical customers. Comparable as a B2B specialty ingredient/delivery platform serving oral dosage reformulation.

TypeDirect peer
Description

SPI Pharma develops specialty excipients and drug delivery platforms including taste-masking and fast-dissolve technologies for pharma and nutraceutical customers. Comparable to Gelteq's taste-masking, palatability, and oral bioavailability focus areas.

9Lubrizol Life Science
TypeDirect peer
Description

Lubrizol's Carbopol polymers are widely used in oral pharmaceutical formulations for controlled release and bioavailability enhancement. Comparable to Gelteq as a polymer-based drug delivery platform serving pharma formulation teams.

TypeBroad incumbent
Description

Lonza is a large global CDMO offering development, manufacturing, and delivery services across biologics, small molecules, and drug product. Comparable as a broader pharmaceutical services incumbent, though Lonza's scale and breadth materially exceed Gelteq's specialized gel platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gelteq

Drug Delivery Technologygelteq.com

Gelteq is an Australian biotech that licenses a patented gel-based oral drug and nutrient delivery platform to pharmaceutical, nutraceutical, and animal health partners globally, addressing bioavailability, taste masking, and swallowing challenges through proprietary gelification technology developed with Monash University.

What Gelteq does

Gelteq is an Australian clinical-stage biotechnology company that has developed and patented a proprietary gel-based oral drug and nutrient delivery platform. Founded around 2016–2017 and headquartered at Monash Innovation Labs in Clayton, Victoria, the company's technology was co-developed with Monash University's Institute of Pharmaceutical Sciences (MIPS), ranked #1 globally for Pharmacy & Pharmacology in the 2024 QS World University Rankings. The core innovation is a gelification process that forms chemically and physically stable matrices capable of simultaneously integrating water-soluble and lipid-soluble compounds, addressing bioavailability and taste-masking challenges that affect over 40% of approved drugs. Preclinical and pharmacokinetic data report a 300% first-hour bioavailability improvement for oil-soluble compounds versus FDA-approved reference products and 38–45% improvement for water-soluble drugs such as antihistamines.

The company monetizes through a B2B licensing and partnership model. Gelteq licenses its proprietary gel formulations for white-label production by pharmaceutical, nutraceutical, and animal health partners; provides fee-for-service contract development and clinical support; and, through select distribution agreements, sells finished gel products directly. Named partners include Phynova and Reducose in pharmaceuticals, Healthy Extracts Inc. for US-based manufacturing and global distribution, Shenzhen Mana Health Management for exclusive China distribution of nutritional products (minimum ~USD 1.3M over three years), IDT Australia for cGMP manufacturing, and Kemin Industries for animal health validation. The company's commercial footprint spans Australia, the United States, and China, with active product candidates in veterinary antiparasitic clinical trials (FDA pathway), preclinical diabetes gels, and an antihistamine gel demonstrating pharmacokinetic gains.

Gelteq Limited is publicly traded on Nasdaq (GLTQ) and the ASX (GTQ), with a market capitalization of approximately $5.2M as of June 2026. The company is unprofitable, has 1–10 employees, and is currently funded in part by a $3.5M convertible debt facility (May 2026) to support clinical programs and commercial scale-up. It has received a Nasdaq minimum bid price deficiency notice with a compliance deadline of September 14, 2026, and its shares have declined approximately 71% over the prior year.

Gelteq firmographics

Firmographics
Name
Gelteq
Legal name
Gelteq Limited
Website
https://gelteq.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Gelteq is an Australian biotech that licenses a patented gel-based oral drug and nutrient delivery platform to pharmaceutical, nutraceutical, and animal health partners globally, addressing bioavailability, taste masking, and swallowing challenges through proprietary gelification technology developed with Monash University.
Ownership category
akta.pro rank

Gelteq industry classification

Industry
Product category
Drug Delivery Technology
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYAFAJACAH
Gelling Agents & Systems (Gelatin, Agar, Gellan, Konjac)
Agriculture & Food Production/Food Ingredients & Additives/Emulsifiers & Stabilizers (Lecithin, Mono/Diglycerides, Stabilizer Systems)
SECONDARYAFAJABAD
Gelatin & Collagen Hydrolysates (Animal-Based Gelling Agents)
Agriculture & Food Production/Food Ingredients & Additives/Starches & Hydrocolloids (Modified Starch, Gums, Thickeners)
SECONDARYCRADAOAD
Hydrocolloids, Thickeners & Gelling Agents (Pectin, Xanthan, Carrageenan, Gelatin)
SECONDARYHLAMAEAM
Generic & Private-Label Veterinary Pharmaceuticals
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMALAO
Specialty & Condition-Specific Nutraceuticals (e.g., Liver, Eye, Endocrine)

Keywords

  • Oral drug delivery
  • Gel-based delivery
  • Nutraceutical formulations
  • Animal health products
  • Bioavailability enhancement

Where Gelteq is headquartered

Location

Headquarters

HQ city
Clayton
HQ country
Australia
HQ region
Oceania

Offices4 records

Markets served

Gelteq business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Technology Licensing: Gelteq licenses its proprietary gel technology to pharmaceutical, nutraceutical, and animal health companies. Partners can white-label existing formulations or develop custom gel products using Gelteq's platform. The company retains full ownership of its intellectual property while enabling partners to manufacture and distribute gel-based products.
  2. Manufacturing & Distribution Partnership: Through partnerships like the Healthy Extracts MoU, Gelteq enables large-scale manufacturing and global distribution of gel products. Healthy Extracts serves as primary manufacturer and distributor while Gelteq provides formulations and technical transfer.
  3. Product Sales (Direct): Direct sales of gel-based nutritional products through distribution agreements. The three-year agreement with Shenzhen Mana Health Management Co. specifies minimum revenue of approximately USD 1.3 million for nutritional products in China.
  4. Contract Development: Fee-for-service formulation development and clinical trial support for pharmaceutical and nutraceutical companies seeking to leverage Gelteq's gel platform for their compounds.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Gelteq product offering

Product offering

Core offering

Gelteq develops, licenses, and white-labels a proprietary patented gel-based oral drug delivery platform that converts pharmaceutical, nutraceutical, and animal health compounds into a stable, ingestible gel matrix. The company provides formulation development, contract research, white-label gel formulations, and partnership-based commercialization across pharmaceutical, nutraceutical, veterinary, and sports nutrition verticals.

Product overview

Gelteq offers a proprietary gel-based oral drug delivery platform as its core technology, enabling the conversion of existing compounds into gel-based formats. The company operates across four main market segments: pharmaceuticals (partnered with Phynova and Reducose), nutraceuticals, pet/veterinary health, and sports performance. Key product candidates include an antiparasitic veterinary drug in clinical trials for FDA approval, diabetes gel products developed with Monash University MIPS, and an antihistamine product showing 38-45% bioavailability improvements. Gelteq provides both custom formulation services and white-label market-ready gel products, with recent expansion through manufacturing partnerships including IDT Australia and Healthy Extracts Inc.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gelteq Gel-Based Oral Drug Delivery Platform
  • Pharmaceutical Gel Products
  • Nutraceutical Gel Products

Quantifiable outcome

  • 300% increase in bioavailability of oil-soluble compounds in the first hour compared to FDA-approved reference product
  • +4 more outcomes

Companies that use Gelteq

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Gelteq technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Gelteq partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and core.

  • Kemin IndustriesmajorStrategic or Co-development Partner · 12 June 2026Successful completion of veterinary palatability trials demonstrating strong canine acceptance across various flavour profiles including products with natural bitter compounds. Results confirmed Gelteq technology's ability to effectively mask bitter flavours while improving palatability, validating the platform for veterinary pharmaceutical applications and supporting partnership discussions with animal health organizations.
  • Healthy Extracts Inc.coreStrategic or Co-development Partner · 11 February 2026Strategic manufacturing and commercial partnership for gel-based nutraceutical products. Healthy Extracts serves as primary manufacturer, commercial seller, and distribution partner using Gelteq's proprietary formulations and technical expertise. Enables large-scale US manufacturing and global distribution while Gelteq retains full IP ownership. Partnership includes plans to expand into China and positions gel-based formats as a growth frontier in functional nutrition.
  • Shenzhen Mana Health Management Co. Ltd.majorChannel Partner/ Reseller/ Distributor · 9 December 2025Three-year sales agreement for distribution of nutritional products in China. Deal expected to generate minimum revenue of approximately USD 1.3 million and represents strategic expansion into China's growing wellness market.
  • IDT AustraliacoreStrategic or Co-development Partner · 17 July 2025MoU for establishment of dedicated local manufacturing facility for gel-based pharmaceutical, nutraceutical, and animal health products. Leverages IDT's more than 50 years of pharmaceutical development and cGMP manufacturing expertise including FDA, TGA, and APVMA regulatory capabilities to support Gelteq's product scale-up for global markets.
  • Monash University - Institute of Pharmaceutical Sciences (MIPS)coreStrategic or Co-development Partner · 1 January 2018Full-time R&D partnership with Monash University, ranked #1 globally in pharmaceutical science (2024 QS World University Rankings). MIPS formed as partnership between Monash University, Monash Institute of Pharmaceutical Science, and Victorian state government to create world-class biotechnology and medical research precinct. Global clients include GSK, Phillips, Roche, and Pfizer. MIPS serves as Gelteq's exclusive research and formulation development partner, with collaboration including development of diabetes-based gel products.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Gelteq competitors and assessment

Company assessment

Direct peers

  • Catalent: Catalent is a global CDMO with proprietary softgel and oral drug delivery platforms serving pharma and consumer health. It is the most direct analog to Gelteq's gel-based oral delivery concept, with a comparable B2B licensing and formulation-development model.
  • Evonik Industries: Evonik's Health Care division supplies specialty excipients and drug delivery technologies (including lipid-based and polymer systems such as EUDRAGIT) to pharmaceutical customers. Direct comparability to Gelteq's delivery-platform and excipient-licensing business model.
  • Roquette: Roquette supplies pharmaceutical excipients including cyclodextrins and starches that address bioavailability challenges for poorly soluble APIs. Comparable in serving pharma formulation teams with solubilization technology, overlapping with Gelteq's core value proposition.
  • Ashland: Ashland's pharmaceutical division provides controlled-release polymers and specialty excipients for oral solid dosage forms. Comparable to Gelteq as a specialty excipient/delivery platform supplier enabling partner drug reformulation.
  • AptarGroup: AptarGroup is a global leader in drug delivery devices and dispensing systems for pharma, consumer health, and food/beverage. Comparable to Gelteq across target end-markets and B2B partnership model, though focused on device rather than formulation delivery.
  • Gattefossé: Gattefossé specializes in lipid-based excipients and oral drug delivery systems for bioavailability enhancement. Directly comparable to Gelteq's dual water/lipid soluble delivery capability and pharma formulation partner model.
  • Colorcon: Colorcon provides controlled-release coatings, excipients, and formulation services to pharma and nutraceutical customers. Comparable as a B2B specialty ingredient/delivery platform serving oral dosage reformulation.
  • SPI Pharma: SPI Pharma develops specialty excipients and drug delivery platforms including taste-masking and fast-dissolve technologies for pharma and nutraceutical customers. Comparable to Gelteq's taste-masking, palatability, and oral bioavailability focus areas.
  • Lubrizol Life Science: Lubrizol's Carbopol polymers are widely used in oral pharmaceutical formulations for controlled release and bioavailability enhancement. Comparable to Gelteq as a polymer-based drug delivery platform serving pharma formulation teams.

Broad incumbents

  • Lonza Group: Lonza is a large global CDMO offering development, manufacturing, and delivery services across biologics, small molecules, and drug product. Comparable as a broader pharmaceutical services incumbent, though Lonza's scale and breadth materially exceed Gelteq's specialized gel platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Gelteq social profiles

Digital presence

Gelteq financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gelteq leadership team

Management profile

Number of profiles

Profiles4 records

Gelteq funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gelteq M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gelteq

What does Gelteq do?

Gelteq develops, licenses, and white-labels a proprietary patented gel-based oral drug delivery platform that converts pharmaceutical, nutraceutical, and animal health compounds into a stable, ingestible gel matrix. The company provides formulation development, contract research, white-label gel formulations, and partnership-based commercialization across pharmaceutical, nutraceutical, veterinary, and sports nutrition verticals.

Is Gelteq a public or private company?

Gelteq is a public company. It is classified as public and is currently operating.

When was Gelteq founded?

Gelteq was founded in 2016. It employs 11 to 50 people.

Where is Gelteq based?

Gelteq is headquartered in Clayton, Australia, in the Oceania region.

How does Gelteq make money?

Four revenue lines are on record. Technology Licensing is the primary driver. The others are manufacturing & Distribution Partnership, product Sales (Direct) and contract Development.

Who are Gelteq's main competitors?

Direct peers on record are Catalent, Evonik Industries, Roquette, Ashland, AptarGroup, Gattefossé, Colorcon, SPI Pharma and Lubrizol Life Science. Lonza Group is listed as a broad incumbent.

Does Gelteq have an API?

No public API is recorded for Gelteq.

What industry is Gelteq in?

Gelteq's product category is Drug Delivery Technology. Its primary akta.pro industry code is AFAJACAH, Gelling Agents & Systems (Gelatin, Agar, Gellan, Konjac), with a secondary code of AFAJABAD, Gelatin & Collagen Hydrolysates (Animal-Based Gelling Agents). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewGELS: Zero FY26 revenue, a record impairment-driven loss and acute funding risk frame the FY27 pipeline pushGelteq Limited reported zero FY26 revenue, a record AUD $25.78m net loss driven by an AUD $18.94m impairment and increased development spending. FY27 priorities include pharmaceutical trials and partnerships, but liquidity pressure, overdue debt, and funding needs remain significant.Defense WorldGelteq Limited (NASDAQ:GELS) Stock Short Interest Report for SeptemberShort interest in Gelteq Limited rose 138.2% to 520,734 shares as of September 30, with a short-interest ratio of 0.2 days. Analysts have a consensus "Sell" rating, and Weiss Ratings reissued a "sell (e+)" rating on September 22. The stock opened at $0.49, below its 50-day moving average of $0.60.American Banking and Market NewsGelteq Limited (NASDAQ:GELS) Stock Short Interest Report for SeptemberGelteq's short interest rose 138.2% to 520,734 shares as of September 30, with 4.9% of shares short sold. Weiss Ratings reaffirmed a sell rating, and the stock opened at $0.49 with a 50-day moving average of $0.60.YahooCould Gelteq’s (GELS) Gel Improve Oral Drug Delivery?Australian biotechnology company Gelteq is developing a proprietary gel-based platform designed to improve the oral delivery of active pharmaceutical ingredients. The company reports that its technology can achieve more than 40% higher bioavailability for water-soluble compounds and significantly faster absorption for oil-soluble ones in preclinical tests. Gelteq is applying this approach across human diabetes treatments, peptide therapies, and animal health products to address formulation challenges.AInvestGelteq (GELS) Plunges 24%: A Volatile capitulation in the Software & Services SectorGelteq (GELS) fell 24.27% intraday, closing at $0.6816 with an 8.70% volume surge. The stock traded below its 200-day moving average and RSI hit 80.05, signaling overbought conditions. Investors are advised to wait for stabilization above $0.70 before re-entering.Investing.comGelteq advances clinical programs across pharmaceutical and veterinary applications By Investing.comGelteq Limited announced progress across multiple clinical and commercial programs during the first half of 2026, including completing planning for its first human clinical trial starting July 1 and commencing a veterinary antiparasitic drug trial with plans to submit an FDA application later in 2026. The biotechnology company also secured up to $3.5 million in debt financing from an institutional investor, established a Center of Excellence in Guangdong Province, China, and completed palatability trials with Kemin Industries, though it received a Nasdaq notice regarding a minimum bid price deficiency.Investing.comGelteq advances clinical programs across pharmaceutical and veterinary applications By Investing.comGelteq Limited announced progress across multiple clinical and commercial programs during the first half of 2026, including completion of planning for its first human clinical trial commencing July 1, 2026, and commencement of a veterinary clinical trial for an antiparasitic drug candidate. The company secured up to $3.5 million in debt financing, completed palatability trials with Kemin Industries, and established a Center of Excellence in Guangdong Province, China, while reporting 188% revenue growth over the last twelve months. Gelteq also received a Nasdaq notice regarding a minimum bid price deficiency after its shares closed below $1.00 for 30 consecutive business days.Investing.comGelteq advances clinical programs across pharmaceutical and veterinary applications By Investing.comGelteq Limited announced progress across multiple clinical and commercial programs during H1 2026, including completing planning for its first human clinical trial starting July 1, 2026 and commencing a veterinary clinical trial for an antiparasitic drug candidate. The biotechnology company also signed a $3.5 million debt financing agreement with an institutional investor, established a Center of Excellence in Guangdong Province, China, and completed palatability trials with Kemin Industries. However, the company received a Nasdaq notice regarding a minimum bid price deficiency, with its stock trading below $1.00 for 30 consecutive business days.Stock TitanGelteq: Human and Vet Trials, $3.5M FinancingGelteq Limited has provided a corporate update on multiple clinical and commercial milestones in 2026, including commencing veterinary clinical trials for an antiparasitic drug candidate targeting FDA approval later this year, completing planning for a human clinical trial expected to begin July 1, 2026, and launching a preclinical diabetes study. The company also secured up to $3.5 million in strategic debt financing and established a Center of Excellence in Guangdong Province, China, while completing commercial product manufacturing for a new East Asian customer.GlobeNewswireGelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple ProgramsGelteq Limited announced multiple clinical and commercial milestones for the first half of 2026, including the commencement of a veterinary clinical trial for an antiparasitic drug candidate, completion of human clinical trial planning expected to begin July 1, 2026, and initiation of a preclinical diabetes study. The company also secured up to US$3.5 million in strategic debt financing, completed palatability trials with Kemin Industries demonstrating strong canine acceptance, manufactured a commercial product for a new East Asian customer, and established a Center of Excellence in Guangdong Province, China.